Rocking Results with Triple Myeloma Combo for Relapsed/Refractory Patients

Myeloma patients (569) who had received one or more prior lines of therapy would receive lenalidomide/dexamethasone or the combination of lenalidomide/dexamethasone/daratumumab. The study was looking at the length of time it took for the disease to return, or progression-free survival (PFS). The rate of progression free survival at 12 months was 83.2% in the len/dex/dara group vs. 60.1% in the len/dex group. The median follow-up was taken at 13.5 months. The depth of response was also compared. According to the study, a significantly higher rate of overall response was observed in the len/dex/dara group (92.9%) vs. the len/dex group (76.4%). And the level of complete response was also better in the len/dex/dara group (43.1%) vs. the len/dex group (19.2%).

"The depth of response and the decrease in the risk of progression seen with this combination is unheard of in  patients with such advanced disease."

 While triple combinations are now the norm in myeloma treatment and always yield better results than a single drugs or doublets, the results of this study show that adding daratumumab to lenalidomide and dex dramatically boosted patients' chances of a good and durable response.  Dr. Rafael Fonseca of the Mayo Clinic, called the results on Twitter "The most impressive trial, ever, in MM."